August 2013: Nimotuzumab in MOGA Australia
Medical Oncology Group of Australia
Similar Posts
Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials
ByInnokeys
Tokyo, Japan (April 25, 2013) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that the first patient has been enrolled in…
ASCO 2013 : Nimotuzumab Abstracts
ByInnokeys
Professor Dirk Strumberg from Germany (center, in blue suit), the principal investigator of phase IIB/IIIA nimotuzumab clinical trial on pancreatic cancer, in…
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM
ByInnokeys
MISSISSAUGA, ON, Dec. 3, 2012 /PRNewswire/ – YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM) today reported that CIMYM BioSciences Inc. has sold its assets relating to nimotuzumab to InnoKeys…
Patent Pending for “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” in numerous countries
ByInnokeys
Application for patents with the title of “Treatment of Patients Diagnosed with pancreatic Ductal Adenocarcinoma Using Monoclonal Antibodies Against the EGFR” are…